{"ticker": {"uuid": "7a8d7452-b686-45df-a039-ed430d38563f", "symbol": "RCKT", "name": "Rocket Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends", "summary": "Rocket Pharmaceuticals (RCKT) stock is gaining investor interest due to its advancing gene therapy pipeline and an extended cash runway, which supports trials into 2027. Despite reporting operating losses, the company modestly beat analyst expectations, and its Danon disease gene", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/rocket-pharmaceuticals-stock-steadies-as-gene-therapy-pipeline-advances/69842149", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-22T22:05:00", "published_display": "22 Jul 2026 22:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Rocket Pharmaceuticals, Inc. (9IP1). It provides a detailed table including each ETF's market value, weight of Rocket Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under man", "url": "https://www.tradingview.com/symbols/MUN-9IP1/etfs/", "source_name": "TradingView", "published_at": "2026-07-20T21:09:27", "published_display": "20 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. \u2013 DUS:9IP1", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (DUS:9IP1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The page i", "url": "https://www.tradingview.com/symbols/DUS-9IP1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T03:40:54", "published_display": "20 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Rocket Pharmaceuticals, Inc., publicly traded under the NASDAQ:RCKTW symbol. The content provides a basic financial overview for investors and traders on TradingView. The presented value focuses on the for", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T16:39:38", "published_display": "19 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to ROCKET PHARMACEUTICALS INC SEC filings (Ticker: RCKTW), including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores, and corresponding end-of-day stock performance. Recent filings include Form ", "url": "https://www.stocktitan.net/sec-filings/RCKTW/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-18T08:09:48", "published_display": "18 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "If You Invested $1,000 in Rocket Pharmaceu (RCKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5udUFjcGNiQVZGSHloQnJBZTZaRUR2TVhmcVU4V1ZVY0thZ1lSSDUxOWNmbG4wSy16TnBXTlo1LTJUU045ZTFsRDdlWnd5Zl9WRnl0TUNvQjVjSWY3M2p1WWczT09sVUZoazA0RFF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:09:15+00:00", "published_display": "13 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake", "summary": "Rocket Pharmaceuticals (RCKT) Principal Accounting Officer, Joseph Manhede, has reported an initial equity stake of 52,576 restricted stock units (RSUs) in the company. These RSUs will convert to common stock on a one-for-one basis, with one-third vesting on May 4, 2027, and the ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-3-rocket-pharmaceuticals-inc-initial-statement-of-beneficial-own-a6a2f51b7cbb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:11:44", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article focuses on the \"Price to book forward\" metric for Rocket Pharmaceuticals, Inc., traded on NASDAQ under the symbol RCKTW. The content is presented within the TradingView platform, emphasizing financial data and market analysis for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T22:09:56", "published_display": "08 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, displaying the stock's market status and offering various ", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:09", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ROCKET PHARMACEUTICALS, INC. SEC Filing", "summary": "This article reports on a recent SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) concerning the proposed sale of securities. The filing details the sale of 10,670 shares of common stock with an aggregate market value of $41,393.20 by an unnamed person through Fidelity ", "url": "https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-0ca66d243c48.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:14:11", "published_display": "07 Jul 2026 19:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards to Rocket Pharmaceuticals (RCKT) director detailed in Form 4", "summary": "Rocket Pharmaceuticals (RCKT) director Mikael Dolsten received routine equity compensation awards, including 22,862 restricted stock units (RSUs) and 64,860 stock options. These awards are compensation-related acquisitions, not open-market trades. Both the RSUs and options fully ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-4552da6baa36.html", "source_name": "Stock Titan", "published_at": "2026-07-07T08:39:30", "published_display": "07 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article provides access to the number of shareholders for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW). It indicates that the specific shareholder data is available under the \"Financials\" section on TradingView. The page highlights that the market was closed and no trades we", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-07T03:39:51", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards granted to RCKT director and 10% owner Roderick Wong", "summary": "Rocket Pharmaceuticals (RCKT) director and 10% owner Roderick Wong has been granted new equity awards, including 27,832 restricted stock units (RSUs) and an option to purchase 78,960 shares of common stock. Both the RSUs and stock options will vest fully on June 18, 2027, with th", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-bb227213ef9f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rocket Pharmaceuticals (RCKT) receives RSU and stock option grants", "summary": "Carsten Boess, a director at Rocket Pharmaceuticals (RCKT), has received significant stock-based compensation, including 22,862 restricted stock units (RSUs) and options for 64,860 shares of common stock. Both the RSUs and stock options will fully vest on June 18, 2027, with the ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-f9b71fa3eb66.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rocket Pharmaceuticals (RCKT) receives RSUs and stock options", "summary": "Rocket Pharmaceuticals (RCKT) director Fady Ibraham Malik has reported receiving equity awards, including 22,862 restricted stock units (RSUs) and stock options for 64,860 shares. Both the RSUs and stock options will vest in full on June 18, 2027, with the stock options having an", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-b404a1828741.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) director receives new RSU and stock option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd1JNWlFBb2lSN04zRkFxQ25FbUIwZTBlNlNkZEV6dFFYcnpGbUMzSjJDdEdwSGN3VTgzNzBickVjVXJyUDVkSG1Od0JhVk53WU5vUnhFZk5UTFVBXzdsSTVXeFFKblNMQ296T3k0cFVtVnpRd1p4UDBUZjZfcFI3TjhidER0eDJZUUZydDRWYTBTc1Q4RGpZTE9MN1BDeXpUN1c2b1dNLXkwaDFrbXdrbUZkNUVaQm9XamZpSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025", "summary": "Levi & Korsinsky, LLP has announced a securities lawsuit alert for investors of Rocket Pharmaceuticals, Inc. (RCKT). Shareholders who suffered losses between February 27, 2025, and May 26, 2025, are encouraged to contact the firm by August 11, 2025, as the company is accused of m", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-rocket-pharmaceuticals-inc-rckt-contact-levi", "source_name": "The National Law Review", "published_at": "2026-07-05T19:41:11", "published_display": "05 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. \u2013 SWB:9IP1", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (SWB:9IP1), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/SWB-9IP1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:40:35", "published_display": "05 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of financial disclosures and SEC filings for Rocket Pharmaceuticals, Inc. (RCKTW), detailing various corporate events such as earnings reports, FDA announcements, and conference presentations spanning from 2024 to 2026. Key advancements ", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T19:09:33", "published_display": "02 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer", "summary": "Rocket Pharmaceuticals (NASDAQ: RCKT) has announced a change in its Principal Accounting Officer. John Militello resigned, effective July 7, 2026, and Joseph Manhede, currently Associate Vice President, Corporate Controller, will assume the role on July 8, 2026. Manhede, a CPA wi", "url": "https://www.stocktitan.net/sec-filings/RCKT/8-k-rocket-pharmaceuticals-inc-reports-material-event-f435d8bf7b47.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:28", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer \u2013 SEC 8-K Filing June 2026", "summary": "Rocket Pharmaceuticals (NASDAQ: RCKT) has announced significant leadership changes in its finance department. John Militello, VP of Finance and Principal Accounting Officer, has resigned, with his departure effective July 7, 2026. Joseph Manhede, who joined the company in April 2", "url": "https://www.minichart.com.sg/2026/06/30/rocket-pharmaceuticals-appoints-joseph-manhede-as-principal-accounting-officer-sec-8-k-filing-june-2026/", "source_name": "Minichart", "published_at": "2026-07-01T07:01:00", "published_display": "01 Jul 2026 07:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark", "summary": "Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) has been dropped from the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Small Cap Comp Growth, 2000 Growth, and 3000E Growth benchmarks. Concurrently, the company was added to the Russell 3000E I", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:34:00", "published_display": "29 Jun 2026 19:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index", "summary": "Rocket Pharmaceuticals, Inc. (RCKT) has been added to the Russell Microcap Value Benchmark Index. This news follows several other index adjustments, including being dropped from the Russell 2000 Growth and Russell 3000E Growth benchmarks, but added to the broader Russell 3000E In", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f322", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:13:17", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark", "summary": "Rocket Pharmaceuticals, Inc. (RCKT) has been dropped from the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being added to the Russell Microcap Value Benchmark Index and the Russell 3000E Index, while also being dropped from th", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-dropped-from-russell-2000-growth-benchmark-ce7f5fdede81f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:13:17", "published_display": "29 Jun 2026 11:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rocket Pharmaceuticals, Inc. \u2013 BOATS:RCKTW", "summary": "This article provides financial data for Rocket Pharmaceuticals, Inc. (RCKTW), specifically focusing on its forward price-to-earnings ratio. It indicates current valuation metrics within the Health Technology and Biotechnology sectors, as presented on the TradingView platform. Th", "url": "https://www.tradingview.com/symbols/BOATS-RCKTW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:40:11", "published_display": "28 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) to recover losses for shareholders affected by alleged securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims Rocket Pharmaceuticals made mislea", "url": "https://www.natlawreview.com/press-releases/lost-money-rocket-pharmaceuticals-inc-rckt-contact-levi-korsinsky-august-11", "source_name": "The National Law Review", "published_at": "2026-06-28T04:40:11", "published_display": "28 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT), urging investors who suffered losses between February 27, 2025, and May 26, 2025, to contact them before August 11, 2025. The lawsuit alleges that Rocket made misleading ", "url": "https://natlawreview.com/press-releases/rocket-pharmaceuticals-inc-rckt-lawsuit-investors-urged-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T04:09:57", "published_display": "28 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rocket Pharmaceuticals, Inc. \u2013 BOATS:RCKTW", "summary": "This article provides a brief financial snippet for Rocket Pharmaceuticals, Inc. under the ticker RCKTW, specifically focusing on its forward price-to-sales ratio. The content is sparse, indicating no active trades and only displaying the stock's name and its listing on the Blue ", "url": "https://www.tradingview.com/symbols/BOATS-RCKTW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:44", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKT", "summary": "This article provides the \"Price to sales forward\" metric for Rocket Pharmaceuticals, Inc. (RCKT) on the Nasdaq Stock Market. It is a financial data point presented by TradingView, with data sourced from ICE Data Services and FactSet. The page indicates that the market was closed", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:22", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:9IP1)", "summary": "This article provides an overview of Rocket Pharmaceuticals, Inc. (TRADEGATE:9IP1) financial actuals and analyst estimates. It includes details on income statements, balance sheets, cash flow, and valuation metrics, along with FAQs about its stock ticker, forecasts, historical pr", "url": "https://www.tradingview.com/symbols/TRADEGATE-9IP1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:28", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKT", "summary": "This article focuses on the enterprise value to revenue forward metric for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). It appears to be a stub or data-oriented piece from TradingView, indicating financial analysis for the biotechnology company. The content primarily lists naviga", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:57", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQcVg4NFVpVXRBRDZtT19ETGxJaW02WEJqUHBidnJncEVhSGZ2QkpRU1loa084b2xJdmZmWkZlSndaSEpmVVYwSjlPdFJUTlJ2LTRvSFk4c3Z1cFF0eFk5dU9hZUttM0pYZTdwdE9sZmdlVk8zbEZJcU5RWlFUd1kwRTZkZ3Z5RFN5X1h3ekRTUTRVd2JBWldxSE9LRmRmRnZy?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Closes $180 Million Sale of Pediatric Priority Review Voucher", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-closes-180-million-114913324.html", "source_name": "MT Newswires", "published_at": "2026-06-12T11:49:13+00:00", "published_display": "12 Jun 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals\u00a0Announces Closing of Sale of\u00a0Rare Pediatric Disease Priority Review Voucher for $180 Million", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-announces-closing-sale-110000892.html", "source_name": "Business Wire", "published_at": "2026-06-12T11:00:00+00:00", "published_display": "12 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where\u2019s the Stock Going?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbUkyekpmQzJPTUY2c0x0djJ1c1lzZkJCWmk4ZzRJZ0hVSmNCQjlTMmtqTDNOQmpUN2JDN29FZ0U3bDRuQ3RDSzZzQlZvOXYzR0RKLVh6MUFNUEczWWdxTDkwV3Y3aG9RMkhSVC1uelV0eWZWYzBwZDdrb1RhaGloY0JoWVBXbU9iWHRCNHg0NUNoWkdQMnhuVktBLUNqekNZMlE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOQ2dldHE5dUgtdnVNVDh3c3RLYndDbVA0MXU1aFJodUlXR3F5cERCV0NVSFBGUFdualhSdVdMU0JlSF96aERkTUxsWWNpZVdXaE1PVExEZjgweExoQ0RBdm4yamJSem9WOXFiMHFfTllpNDlSYlE0dFBCQlBsR1BmcjA1VHliLU1YWTg0VzUyWFVBdFJxdnlHXzhKS3NSaVgycnVKcFk2Skh1VW8?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-apos-cardiac-programs-161854069.html", "source_name": "MT Newswires", "published_at": "2026-05-08T16:18:54+00:00", "published_display": "08 May 2026 16:18", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rocket-pharmaceuticals-q1-earnings-snapshot-200827882.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:08:27+00:00", "published_display": "07 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOaWk0cE5icEFUUjB1Qkd1VWgtVUxHazlYclpvUDdfV3ctRTdwVlFhZnJxU3FuZm5rQnFBNXhBNTROcjNmeWd5TXVnUEtFb2swQWJEcldrVVlSd2tPRXkyS015SWRwUEdDc0JTU0lqYjVLaUh1Nl8wY0lfQU8tZHFCTjk3SGZwa3o4bzE1bVhaZjMxcUhGSlNmZUo3Sy02Z0U?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQQzFIczJEUXB0a3ZrRXBFb1JWUllsclh3LUM1dVdWZ3BGdS1YYkU3dDY5elUwWklMLVZlek91cEtMYVBCanJzclVfX2xHeVRBdEJrYkZXaTBSbWNpS2RnTm1iekxfejVxVzhiVFdXNkphOUcyRXhvNDVkMkVEdXVuOVRNbmpPV3FmNjFaZ3gwZGwyTHpnZW50ZFJGemxWck9Oc01NTFg4aVFvTXNHQmtLQlBoUjU1STB0ZER5T1ViTi1EbUxDeFNzYnN2S0JJNzc1TmxLc3hNM0ZRbURld0FqWkZyRFM2QVVad2V2UdIB8gFBVV95cUxQRFhfd0tac3JhZUhxbW1UekZRR2NicHBUTklJMTY2Qk82cXFCNUlwYUNnRTR2U2VOdDJ0aEViRjhiZldBOC1STzFmZkNnSkRqMms4RF9pQnZmUFhYd3g4cmE1cExqODdEeUZ1QVgxY1dLeThWTDV6dWNtT2Eza19oVEZsOW1KU2k4UGt5RC1EUXJFVmViSEx1T2taRG1GYXlNNDNqc2tSdl82OHFfaXE0WHVYdG1kVk9sMWVHQTRrSU84eDZZNDZoSUVyenI1X3N0MGlqay1ZbWVPREk4NEhFdlNqVFFDa0sxNXRjOVBmNkpzZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQmEyc21sT3ZSb0dPOWN3Vk9UNzY4TW1PaUYyR01ZUVpKRTQ1Tkx4REtXTHAwTmVsb3lSRXVXbGFGR21Dd3A4YXdfY0ZsSDdoSEV3SHp6Tms1dHl1c0pqNVVNM0E2eWtRUHJoN3FOTXh0c1ZFbGVEX2llU1VPSk5pVUFqY21jVzVZQkhXdlhNb0NPaDEtZllXNzVLX01BRzNnUGhKMzR2QQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdUlsNm1sblZqTnBqanhJU2VocXpWN2dhb3N2dmRqZTZvSEFRLVpzYVY2ZFZBMXFQN3pydVBnc05GN2x6dHBUSWRLbEhqRFIxcWhmdGt6dEZ3V1VDNW1jdm9MYUloTEQtb3hUcm5MWXA3Q0w0bFhoTmRLV2JOOGVEOWE1R1NjczRIZ2FlZXd3dDdLOVZuY3ExUzdXeUJOVUt0dWVJVmF3?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "US Premarket Movers: Argan, Rocket Pharmaceuticals, Unity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVVJwY2NrNFpLZ3BWR3JJakltQkk3LTlxQ2FhbTlCVmp5cDNhY0RDYmpFR1Z5cmI4endvLVFWbUg3UHVxUEU1UWloRmlrMW9XZWRsT3ZTSTJFVHd4MVBjQTlEbHlmTmVxN29DRFRmcno1VTRuUXlMazJGanZlWGV4cnN1WHd3X2NjYVpqVmZNYV8xMFczNUFXQ2htdGxYX1dqMDFTZEZPOHVzWFBv?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharma wins FDA nod for gene therapy (update)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOdUJoSFprR1dhSE0yM3FaMXdTaWN4Z0NiSmFVQ25CMnFoNXV2WFJzNXVlRUdVVmRESkpjcnlVTUZNTTBlc2J4eVNvN3NmS2pOZHl1VmtEQ09UMDVaNkZObGczbndubFRmYl9CSUtST2VYUGs2RGN6UW5yU2FsQW0zOERsZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Rocket Pharmaceuticals (RCKT) KRESLADI gene therapy and voucher", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTnRzSFN1SmlmYmNOTFRqU19sVWtiWjFObDhMMUFFeHp3OE9NMmJFSy1XTS1YdXRrOUVsVlQ5VEFhUUdLbi0yUjRMSEZlUVZqREJKbVBwQ2szeXVadEZYNER3MzFJR1ZKeEFEVFVXc3dtLWVOQVh2NjdSTXltbnE1bG9UVzNkY2NvSHBpMU1GVXpmNGtfSXE1NDJLYm41VzF2Nk9mOWc4R1V6V0pnN2N1UWxQRWJuQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Disaggregates Rocket Pharmaceuticals Holdings (NASDAQ: RCKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPSXBHRGh4THNDdHpORHVTZjB1aU9uZzRPX0NsUjJnWXhUVlBkYlBtWmRvRTdoWldpVHhoZkNxbVIxNkNlQm51d2lVR1ltZm1sdUFzT3N4ZGVsSWNGQnM4UDlwdFBXczExcERoWVc1YllIRUtVZW1sVERIU0pCdnhSUjdPWE15RjBiazVUcVBaUzF1VDZCMzZNVEhUSEI5N1Z2OXd4R0ZKU2VTa2lCYkZDMUNmQl9ZNE55RW4wdmMxeHZ1ZlJsb2xfN0tZNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Rocket Pharma shares fall 15% despite FDA nod for childhood disorder treatment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORDhWNUJrZHdudS1iUDlzYUJld2xmSzExNEc0WUd0aUtrUGp5RmZOT0xBSndfSl95TU1JNHZZY25yR1Y5cEJlYWY3Y3luSndreEV5akx0NjRfZ25XVVRfZUZmOXB5T0t6R3VzeHVWV2sxalZaOFU5aEpRUjdmV0diRmFGWUJibnFJR21xeGVjWHU5Z0U?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQVlFtdTh1a082MUc3RGotNVU1NUZaamY0OXdvbC1lcUtZX0dCV2Z5bk00cDdiTjk0a1Z6U2V0UUNYeU5renpIWi0yaS1DLXhfZ0NGUWpVSFZwVlNpVGZGUFNWZ1VENGZjcU1FZjFQbzVDcWlOODJxSGlHTjZpN21mdWQ0eVFyUWZRLUxhV3pxcw?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Possible Signal As Rocket Pharmaceuticals Insiders Sell US$1.1m In Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends", "summary": "Rocket Pharmaceuticals (RCKT) stock is gaining investor interest due to its advancing gene therapy pipeline and an extended cash runway, which supports trials into 2027. Despite reporting operating losses, the company modestly beat analyst expectations, and its Danon disease gene", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/rocket-pharmaceuticals-stock-steadies-as-gene-therapy-pipeline-advances/69842149", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-22T22:05:00", "published_display": "22 Jul 2026 22:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Rocket Pharmaceuticals, Inc. (9IP1). It provides a detailed table including each ETF's market value, weight of Rocket Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under man", "url": "https://www.tradingview.com/symbols/MUN-9IP1/etfs/", "source_name": "TradingView", "published_at": "2026-07-20T21:09:27", "published_display": "20 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. \u2013 DUS:9IP1", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (DUS:9IP1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The page i", "url": "https://www.tradingview.com/symbols/DUS-9IP1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T03:40:54", "published_display": "20 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Rocket Pharmaceuticals, Inc., publicly traded under the NASDAQ:RCKTW symbol. The content provides a basic financial overview for investors and traders on TradingView. The presented value focuses on the for", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T16:39:38", "published_display": "19 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to ROCKET PHARMACEUTICALS INC SEC filings (Ticker: RCKTW), including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores, and corresponding end-of-day stock performance. Recent filings include Form ", "url": "https://www.stocktitan.net/sec-filings/RCKTW/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-18T08:09:48", "published_display": "18 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Rocket Pharmaceu (RCKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5udUFjcGNiQVZGSHloQnJBZTZaRUR2TVhmcVU4V1ZVY0thZ1lSSDUxOWNmbG4wSy16TnBXTlo1LTJUU045ZTFsRDdlWnd5Zl9WRnl0TUNvQjVjSWY3M2p1WWczT09sVUZoazA0RFF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:09:15+00:00", "published_display": "13 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake", "summary": "Rocket Pharmaceuticals (RCKT) Principal Accounting Officer, Joseph Manhede, has reported an initial equity stake of 52,576 restricted stock units (RSUs) in the company. These RSUs will convert to common stock on a one-for-one basis, with one-third vesting on May 4, 2027, and the ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-3-rocket-pharmaceuticals-inc-initial-statement-of-beneficial-own-a6a2f51b7cbb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:11:44", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article focuses on the \"Price to book forward\" metric for Rocket Pharmaceuticals, Inc., traded on NASDAQ under the symbol RCKTW. The content is presented within the TradingView platform, emphasizing financial data and market analysis for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T22:09:56", "published_display": "08 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, displaying the stock's market status and offering various ", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:09", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ROCKET PHARMACEUTICALS, INC. SEC Filing", "summary": "This article reports on a recent SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) concerning the proposed sale of securities. The filing details the sale of 10,670 shares of common stock with an aggregate market value of $41,393.20 by an unnamed person through Fidelity ", "url": "https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-0ca66d243c48.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:14:11", "published_display": "07 Jul 2026 19:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards to Rocket Pharmaceuticals (RCKT) director detailed in Form 4", "summary": "Rocket Pharmaceuticals (RCKT) director Mikael Dolsten received routine equity compensation awards, including 22,862 restricted stock units (RSUs) and 64,860 stock options. These awards are compensation-related acquisitions, not open-market trades. Both the RSUs and options fully ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-4552da6baa36.html", "source_name": "Stock Titan", "published_at": "2026-07-07T08:39:30", "published_display": "07 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKTW", "summary": "This article provides access to the number of shareholders for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKTW). It indicates that the specific shareholder data is available under the \"Financials\" section on TradingView. The page highlights that the market was closed and no trades we", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-07T03:39:51", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards granted to RCKT director and 10% owner Roderick Wong", "summary": "Rocket Pharmaceuticals (RCKT) director and 10% owner Roderick Wong has been granted new equity awards, including 27,832 restricted stock units (RSUs) and an option to purchase 78,960 shares of common stock. Both the RSUs and stock options will vest fully on June 18, 2027, with th", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-bb227213ef9f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rocket Pharmaceuticals (RCKT) receives RSU and stock option grants", "summary": "Carsten Boess, a director at Rocket Pharmaceuticals (RCKT), has received significant stock-based compensation, including 22,862 restricted stock units (RSUs) and options for 64,860 shares of common stock. Both the RSUs and stock options will fully vest on June 18, 2027, with the ", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-f9b71fa3eb66.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rocket Pharmaceuticals (RCKT) receives RSUs and stock options", "summary": "Rocket Pharmaceuticals (RCKT) director Fady Ibraham Malik has reported receiving equity awards, including 22,862 restricted stock units (RSUs) and stock options for 64,860 shares. Both the RSUs and stock options will vest in full on June 18, 2027, with the stock options having an", "url": "https://www.stocktitan.net/sec-filings/RCKT/form-4-rocket-pharmaceuticals-inc-insider-trading-activity-b404a1828741.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:39:51", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) director receives new RSU and stock option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd1JNWlFBb2lSN04zRkFxQ25FbUIwZTBlNlNkZEV6dFFYcnpGbUMzSjJDdEdwSGN3VTgzNzBickVjVXJyUDVkSG1Od0JhVk53WU5vUnhFZk5UTFVBXzdsSTVXeFFKblNMQ296T3k0cFVtVnpRd1p4UDBUZjZfcFI3TjhidER0eDJZUUZydDRWYTBTc1Q4RGpZTE9MN1BDeXpUN1c2b1dNLXkwaDFrbXdrbUZkNUVaQm9XamZpSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025", "summary": "Levi & Korsinsky, LLP has announced a securities lawsuit alert for investors of Rocket Pharmaceuticals, Inc. (RCKT). Shareholders who suffered losses between February 27, 2025, and May 26, 2025, are encouraged to contact the firm by August 11, 2025, as the company is accused of m", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-rocket-pharmaceuticals-inc-rckt-contact-levi", "source_name": "The National Law Review", "published_at": "2026-07-05T19:41:11", "published_display": "05 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. \u2013 SWB:9IP1", "summary": "This article provides financial information for Rocket Pharmaceuticals, Inc. (SWB:9IP1), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/SWB-9IP1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:40:35", "published_display": "05 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of financial disclosures and SEC filings for Rocket Pharmaceuticals, Inc. (RCKTW), detailing various corporate events such as earnings reports, FDA announcements, and conference presentations spanning from 2024 to 2026. Key advancements ", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKTW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T19:09:33", "published_display": "02 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer", "summary": "Rocket Pharmaceuticals (NASDAQ: RCKT) has announced a change in its Principal Accounting Officer. John Militello resigned, effective July 7, 2026, and Joseph Manhede, currently Associate Vice President, Corporate Controller, will assume the role on July 8, 2026. Manhede, a CPA wi", "url": "https://www.stocktitan.net/sec-filings/RCKT/8-k-rocket-pharmaceuticals-inc-reports-material-event-f435d8bf7b47.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:28", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer \u2013 SEC 8-K Filing June 2026", "summary": "Rocket Pharmaceuticals (NASDAQ: RCKT) has announced significant leadership changes in its finance department. John Militello, VP of Finance and Principal Accounting Officer, has resigned, with his departure effective July 7, 2026. Joseph Manhede, who joined the company in April 2", "url": "https://www.minichart.com.sg/2026/06/30/rocket-pharmaceuticals-appoints-joseph-manhede-as-principal-accounting-officer-sec-8-k-filing-june-2026/", "source_name": "Minichart", "published_at": "2026-07-01T07:01:00", "published_display": "01 Jul 2026 07:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark", "summary": "Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) has been dropped from the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Small Cap Comp Growth, 2000 Growth, and 3000E Growth benchmarks. Concurrently, the company was added to the Russell 3000E I", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:34:00", "published_display": "29 Jun 2026 19:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index", "summary": "Rocket Pharmaceuticals, Inc. (RCKT) has been added to the Russell Microcap Value Benchmark Index. This news follows several other index adjustments, including being dropped from the Russell 2000 Growth and Russell 3000E Growth benchmarks, but added to the broader Russell 3000E In", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f322", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:13:17", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark", "summary": "Rocket Pharmaceuticals, Inc. (RCKT) has been dropped from the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being added to the Russell Microcap Value Benchmark Index and the Russell 3000E Index, while also being dropped from th", "url": "https://www.marketscreener.com/news/rocket-pharmaceuticals-inc-nasdaqgm-rckt-dropped-from-russell-2000-growth-benchmark-ce7f5fdede81f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:13:17", "published_display": "29 Jun 2026 11:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rocket Pharmaceuticals, Inc. \u2013 BOATS:RCKTW", "summary": "This article provides financial data for Rocket Pharmaceuticals, Inc. (RCKTW), specifically focusing on its forward price-to-earnings ratio. It indicates current valuation metrics within the Health Technology and Biotechnology sectors, as presented on the TradingView platform. Th", "url": "https://www.tradingview.com/symbols/BOATS-RCKTW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:40:11", "published_display": "28 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) to recover losses for shareholders affected by alleged securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims Rocket Pharmaceuticals made mislea", "url": "https://www.natlawreview.com/press-releases/lost-money-rocket-pharmaceuticals-inc-rckt-contact-levi-korsinsky-august-11", "source_name": "The National Law Review", "published_at": "2026-06-28T04:40:11", "published_display": "28 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT), urging investors who suffered losses between February 27, 2025, and May 26, 2025, to contact them before August 11, 2025. The lawsuit alleges that Rocket made misleading ", "url": "https://natlawreview.com/press-releases/rocket-pharmaceuticals-inc-rckt-lawsuit-investors-urged-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T04:09:57", "published_display": "28 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rocket Pharmaceuticals, Inc. \u2013 BOATS:RCKTW", "summary": "This article provides a brief financial snippet for Rocket Pharmaceuticals, Inc. under the ticker RCKTW, specifically focusing on its forward price-to-sales ratio. The content is sparse, indicating no active trades and only displaying the stock's name and its listing on the Blue ", "url": "https://www.tradingview.com/symbols/BOATS-RCKTW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:44", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKT", "summary": "This article provides the \"Price to sales forward\" metric for Rocket Pharmaceuticals, Inc. (RCKT) on the Nasdaq Stock Market. It is a financial data point presented by TradingView, with data sourced from ICE Data Services and FactSet. The page indicates that the market was closed", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:22", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:9IP1)", "summary": "This article provides an overview of Rocket Pharmaceuticals, Inc. (TRADEGATE:9IP1) financial actuals and analyst estimates. It includes details on income statements, balance sheets, cash flow, and valuation metrics, along with FAQs about its stock ticker, forecasts, historical pr", "url": "https://www.tradingview.com/symbols/TRADEGATE-9IP1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:28", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. \u2013 NASDAQ:RCKT", "summary": "This article focuses on the enterprise value to revenue forward metric for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). It appears to be a stub or data-oriented piece from TradingView, indicating financial analysis for the biotechnology company. The content primarily lists naviga", "url": "https://www.tradingview.com/symbols/NASDAQ-RCKT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:57", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQcVg4NFVpVXRBRDZtT19ETGxJaW02WEJqUHBidnJncEVhSGZ2QkpRU1loa084b2xJdmZmWkZlSndaSEpmVVYwSjlPdFJUTlJ2LTRvSFk4c3Z1cFF0eFk5dU9hZUttM0pYZTdwdE9sZmdlVk8zbEZJcU5RWlFUd1kwRTZkZ3Z5RFN5X1h3ekRTUTRVd2JBWldxSE9LRmRmRnZy?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Closes $180 Million Sale of Pediatric Priority Review Voucher", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-closes-180-million-114913324.html", "source_name": "MT Newswires", "published_at": "2026-06-12T11:49:13+00:00", "published_display": "12 Jun 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals\u00a0Announces Closing of Sale of\u00a0Rare Pediatric Disease Priority Review Voucher for $180 Million", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-announces-closing-sale-110000892.html", "source_name": "Business Wire", "published_at": "2026-06-12T11:00:00+00:00", "published_display": "12 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where\u2019s the Stock Going?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbUkyekpmQzJPTUY2c0x0djJ1c1lzZkJCWmk4ZzRJZ0hVSmNCQjlTMmtqTDNOQmpUN2JDN29FZ0U3bDRuQ3RDSzZzQlZvOXYzR0RKLVh6MUFNUEczWWdxTDkwV3Y3aG9RMkhSVC1uelV0eWZWYzBwZDdrb1RhaGloY0JoWVBXbU9iWHRCNHg0NUNoWkdQMnhuVktBLUNqekNZMlE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOQ2dldHE5dUgtdnVNVDh3c3RLYndDbVA0MXU1aFJodUlXR3F5cERCV0NVSFBGUFdualhSdVdMU0JlSF96aERkTUxsWWNpZVdXaE1PVExEZjgweExoQ0RBdm4yamJSem9WOXFiMHFfTllpNDlSYlE0dFBCQlBsR1BmcjA1VHliLU1YWTg0VzUyWFVBdFJxdnlHXzhKS3NSaVgycnVKcFk2Skh1VW8?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rocket-pharmaceuticals-apos-cardiac-programs-161854069.html", "source_name": "MT Newswires", "published_at": "2026-05-08T16:18:54+00:00", "published_display": "08 May 2026 16:18", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rocket-pharmaceuticals-q1-earnings-snapshot-200827882.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:08:27+00:00", "published_display": "07 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOaWk0cE5icEFUUjB1Qkd1VWgtVUxHazlYclpvUDdfV3ctRTdwVlFhZnJxU3FuZm5rQnFBNXhBNTROcjNmeWd5TXVnUEtFb2swQWJEcldrVVlSd2tPRXkyS015SWRwUEdDc0JTU0lqYjVLaUh1Nl8wY0lfQU8tZHFCTjk3SGZwa3o4bzE1bVhaZjMxcUhGSlNmZUo3Sy02Z0U?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQmEyc21sT3ZSb0dPOWN3Vk9UNzY4TW1PaUYyR01ZUVpKRTQ1Tkx4REtXTHAwTmVsb3lSRXVXbGFGR21Dd3A4YXdfY0ZsSDdoSEV3SHp6Tms1dHl1c0pqNVVNM0E2eWtRUHJoN3FOTXh0c1ZFbGVEX2llU1VPSk5pVUFqY21jVzVZQkhXdlhNb0NPaDEtZllXNzVLX01BRzNnUGhKMzR2QQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdUlsNm1sblZqTnBqanhJU2VocXpWN2dhb3N2dmRqZTZvSEFRLVpzYVY2ZFZBMXFQN3pydVBnc05GN2x6dHBUSWRLbEhqRFIxcWhmdGt6dEZ3V1VDNW1jdm9MYUloTEQtb3hUcm5MWXA3Q0w0bFhoTmRLV2JOOGVEOWE1R1NjczRIZ2FlZXd3dDdLOVZuY3ExUzdXeUJOVUt0dWVJVmF3?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Premarket Movers: Argan, Rocket Pharmaceuticals, Unity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVVJwY2NrNFpLZ3BWR3JJakltQkk3LTlxQ2FhbTlCVmp5cDNhY0RDYmpFR1Z5cmI4endvLVFWbUg3UHVxUEU1UWloRmlrMW9XZWRsT3ZTSTJFVHd4MVBjQTlEbHlmTmVxN29DRFRmcno1VTRuUXlMazJGanZlWGV4cnN1WHd3X2NjYVpqVmZNYV8xMFczNUFXQ2htdGxYX1dqMDFTZEZPOHVzWFBv?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharma wins FDA nod for gene therapy (update)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOdUJoSFprR1dhSE0yM3FaMXdTaWN4Z0NiSmFVQ25CMnFoNXV2WFJzNXVlRUdVVmRESkpjcnlVTUZNTTBlc2J4eVNvN3NmS2pOZHl1VmtEQ09UMDVaNkZObGczbndubFRmYl9CSUtST2VYUGs2RGN6UW5yU2FsQW0zOERsZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Rocket Pharmaceuticals (RCKT) KRESLADI gene therapy and voucher", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTnRzSFN1SmlmYmNOTFRqU19sVWtiWjFObDhMMUFFeHp3OE9NMmJFSy1XTS1YdXRrOUVsVlQ5VEFhUUdLbi0yUjRMSEZlUVZqREJKbVBwQ2szeXVadEZYNER3MzFJR1ZKeEFEVFVXc3dtLWVOQVh2NjdSTXltbnE1bG9UVzNkY2NvSHBpMU1GVXpmNGtfSXE1NDJLYm41VzF2Nk9mOWc4R1V6V0pnN2N1UWxQRWJuQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Disaggregates Rocket Pharmaceuticals Holdings (NASDAQ: RCKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPSXBHRGh4THNDdHpORHVTZjB1aU9uZzRPX0NsUjJnWXhUVlBkYlBtWmRvRTdoWldpVHhoZkNxbVIxNkNlQm51d2lVR1ltZm1sdUFzT3N4ZGVsSWNGQnM4UDlwdFBXczExcERoWVc1YllIRUtVZW1sVERIU0pCdnhSUjdPWE15RjBiazVUcVBaUzF1VDZCMzZNVEhUSEI5N1Z2OXd4R0ZKU2VTa2lCYkZDMUNmQl9ZNE55RW4wdmMxeHZ1ZlJsb2xfN0tZNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Rocket Pharma shares fall 15% despite FDA nod for childhood disorder treatment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORDhWNUJrZHdudS1iUDlzYUJld2xmSzExNEc0WUd0aUtrUGp5RmZOT0xBSndfSl95TU1JNHZZY25yR1Y5cEJlYWY3Y3luSndreEV5akx0NjRfZ25XVVRfZUZmOXB5T0t6R3VzeHVWV2sxalZaOFU5aEpRUjdmV0diRmFGWUJibnFJR21xeGVjWHU5Z0U?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQVlFtdTh1a082MUc3RGotNVU1NUZaamY0OXdvbC1lcUtZX0dCV2Z5bk00cDdiTjk0a1Z6U2V0UUNYeU5renpIWi0yaS1DLXhfZ0NGUWpVSFZwVlNpVGZGUFNWZ1VENGZjcU1FZjFQbzVDcWlOODJxSGlHTjZpN21mdWQ0eVFyUWZRLUxhV3pxcw?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Possible Signal As Rocket Pharmaceuticals Insiders Sell US$1.1m In Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 63, "sentiment_summary": {"positive": 8, "negative": 9, "neutral": 46, "score": 48, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 21.2, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 7.36, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 3.44, "latest_week": "2026-07-17", "one_week_move": -12.0, "four_week_move": 2.7, "twelve_week_move": -2.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.139787, "market_dynamics_buy_signal": false, "relative_strength": -11.104711, "fair_value_gap": -72.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.8869, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.0% over one week, +2.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 12}, {"label": "simplywall.st", "count": 5}, {"label": "The National Law Review", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Ad-hoc-news.de", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 15}, {"label": "Regulatory and legal", "count": 6}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-12.0% over one week, +2.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends"}], "updated_at": "2026-07-23T10:29:58.703479+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}